The size of the minimally invasive surgical instruments market in the Middle East & Africa is forecasted to grow USD 3.12 billion by 2027 from USD 1.80 billion in 2022, hiking at a CAGR of 11.65% from 2022 to 2027.
The increasing number of surgical procedures is majorly driving the minimally invasive surgical instruments market in MEA. In addition, the growing geriatric population significantly influences the demand for surgical instruments because the senior population is more prone to various chronic diseases such as cardiovascular, surgical intervention, and Orthopedic require effective surgical treatments.
MIS operations are much less expensive than in-patient and traditional open surgeries with comparable outcomes, resulting in a significant increase in value for patients and insurance providers. This pattern is expected to continue in the future years. In addition, the technological advancements, increasing innovative surgical procedures, and the growing adoption of advanced robotics in ASCs and fuelling the market growth. This technology allows physicians to conduct Minimally invasive surgery instead of open surgery in complicated procedures to reduce patients' risk and enhance recovery time.
Surgical robots have revolutionized the field of minimally invasive surgery (MIS), and surgeons are increasingly accepting of them. The MIS provides various advantages over open surgical techniques, such as minimally invasive surgery associated with less pain, fewer complications, and minimizing hospital stay. The surgeries like gynecological, cardiothoracic, urogynecology, pediatric, gastroenterology, and heart surgery are conducted through minimally invasive surgical procedures. The increasing investment and funding by the government and private organizations for the advancement of healthcare infrastructure and research and development activities are encouraging market growth. The demand for laparoscopic surgery has significantly increased in the recent past, which is estimated to accelerate the market growth. Key players in the region are adopting market strategies like collaborations, acquisitions, and mergers to launch novel laparoscopic technology and advanced instruments.
However, the high requirement of capital investments and the high degree of consolidation among the market players restrict the market growth. On the other hand, a lack of skilled professionals and a strict regulatory framework pose a market growth challenge.
This research report on the MEA minimally invasive surgical instruments market has been segmented and sub-segmented into the following categories:
By End Users:
The MEA is projected to witness a moderate share in the global market during the forecast period. The growth is fuelled by the increasing geriatric population, initiatives by the government through medical tourism, and supportive government policies.
South Africa held the largest share of the market in 2020, and it is anticipated to register a prominent share during the forecast period. The factors such as the higher acceptance rate of minimally invasive surgeries, increasing per capita income, growing healthcare expenditure, and improved patient quality of life are propelling the market growth.
The UAE is expected to record a moderate share in the MEA market during the forecast period owing to the rising number of surgeries among the aging population, increasing prevalence of lifestyle-based and chronic disorders, and technological advancements in the healthcare sector.
On the other hand, Saudi Arabia is projected to grow at a healthy CAGR during the forecast period due to the rise in the prevalence of chronic diseases, increasing demand for minimally invasive surgeries, and technological advancements. In addition, the number of hospitals is increasing, the ministry of healthcare is supporting better infrastructure development in the country and contributing to market growth.
KEY MARKET PLAYERS:
Companies playing a significant role in the MEA minimally invasive surgical instruments market profiled in this report are Medtronic plc (Ireland), Ethicon, Inc. (U.S.), Aesculap, Inc. (Germany), Stryker Corporation (U.S.), Smith & Nephew (U.K.), ConMed Corporation (U.S.), Abbott Laboratories (U.S.), Applied Biomedical Resources Corporation (U.S.), Microline Surgical (Japan) and Zimmer Biomet (U.S.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com